Vaxcyte Inc. Advances Phase 2 Study of VAX-31 Optimized Dose for Infants, Targeting Broad-Spectrum Protection Against Pneumococcal Disease
Vaxcyte Inc., a clinical-stage vaccine innovation company, has announced the advancement of its modified VAX-31 infant Phase 2 randomized, dose-finding study to the third and final stage. This study is focused on evaluating the safety, tolerability, and immunogenicity of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, in comparison to Prevnar 20 (PCV20) in healthy infants. The study protocol has been modified to include a new dose arm, the VAX-31 Optimized Dose, with the majority of serotypes dosed at 4.4mcg and the balance at 3.3mcg, while discontinuing enrollment in the Low Dose arm. The study aims to enroll approximately 900 participants, with the Middle and High Dose arms continuing as planned. Vaxcyte intends to release topline data from the primary immunization series and the booster dose either sequentially or together by the end of the first half of 2027. Results from the study have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9522336-en) on September 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.